OQROStart free trial
Politician trade (House)

Johnson & Johnson (JNJ): Rep. Lisa C. McClain (MI09) disclosed a purchase $1K–$15K

Rep. Lisa C. McClain (MI09) disclosed a purchase of Johnson & Johnson in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
22 days
Disclosure lag
Traded
Oct 30, 2025
Disclosed
Nov 21, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  4. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  5. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  6. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  7. Sep 4, 2025Insider · 4 days before an 8-KOfficer sold ~$10M of JNJ shares in the open market
  8. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
  9. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  10. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date
  11. Oct 10, 2025Congress · 1 personMembers of Congress: 2 sales
  12. Oct 14, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  13. Oct 16, 2025Federal contract · $384K obligatedDepartment of Defense awarded Johnson & Johnson: $384K obligated to date
  14. Oct 17, 2025InsiderOfficer sold ~$4.19M of JNJ shares in the open market
  15. Oct 30, 2025 · this disclosureCongressDisclosed purchase of JNJ — reported range $1,001 - $15,000

What came next

  1. Oct 30, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  2. Oct 31, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  3. Nov 5, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Nov 13, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  5. Nov 20, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  6. Nov 26, 2025Insider · Their first buy on recordDirector purchased ~$258K of JNJ shares in the open market
  7. Dec 9, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  8. Dec 10, 2025Federal contract · $8K obligatedDepartment of Defense awarded Johnson & Johnson: $7.7K obligated to date
  9. Dec 18, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  10. Jan 21, 2026Company filing · Form 8-K · ResultsReported its results
  11. Jan 21, 2026FDARecall: MONARCH Platform, Bronchoscopy, Catalog Numbers: MON-000005-01 , MON-000005-01R , MON-000006 , MON-000006-RFB, MON-000008 with software
  12. Jan 23, 2026CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  13. Jan 26, 2026Insider · 1 personInsiders: 2 sales (~$22.1M)
  14. Jan 27, 2026FDAFDA drug approval: Darzalex Faspro
  15. Jan 27, 2026FDARecall: Impella RP. Product Code: 0046-0011.
  16. Jan 27, 2026FDARecall: Impella RP Flex with SmartAssist. Product Code: 1000323.
  17. Jan 27, 2026FDARecall: Impella RP with SmartAssist. Product Code: 0046-0035.
  18. Feb 5, 20265% stakeThe Vanguard Group reported a passive stake (13G) of 10.1%
  19. Feb 6, 2026FDAFDA device clearance: MONOCRYL™ Plus Antibacterial Poliglecaprone – 25 (Monofilament), Sterile Synthetic Absorbable Surgical Suture
  20. Feb 13, 2026FDAFDA drug approval: Rybrevant Faspro
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Rep. Lisa C. McClain (MI09)

The full history of Rep. Lisa C. McClain (MI09) is on the profile page.

How this filing works

Explore the data

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data